The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease

[Background] There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. The Named Patient Program in Europe included patients with advanced chronic hepatitis C, a life expectancy of less than 12 months and no other treatment options.

Detalles Bibliográficos
Autores: Young, Jim, Weis, Nina, Hofer, Harald, Irving, William, Weiland, Ola, Giostra, Emiliano, Pascasio, Juan Manuel, Castells, Lluis, Prieto, Martín, Postema, Roelien, Lefevre, Cinira, Evans, David, Bucher, Heiner C., Calleja, José Luis
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/180338
Acceso en línea:http://hdl.handle.net/10261/180338
Access Level:acceso abierto
Palabra clave:Daclatasvir
Direct-acting antivirals
Effectiveness
Hepatitis C
Sofosbuvir
Descripción
Sumario:[Background] There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. The Named Patient Program in Europe included patients with advanced chronic hepatitis C, a life expectancy of less than 12 months and no other treatment options.

Similares en LA Referencia